Showing 3851-3860 of 5956 results for "".
- Oculis Completes Enrollment in Both DIAMOND Phase 3 Trials of OCS-01 in DMEhttps://modernod.com/news/oculis-completes-enrollment-in-both-diamond-phase-3-trials-of-ocs-01-in-dme/2482732/Oculis Holding said it has completed enrollment in both phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME. The trials are designed as pivotal registration studies to support global marketing applications including NDA submission and approval by t
- Atsena Therapeutics Secures $150 Million to Advance Investigational Ocular Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-150-million-to-advance-investigational-ocular-gene-therapy/2482726/Atsena Therapeutics has closed an oversubscribed $150 million Series C financing, which will be used to advance Atsena’s lead gene therapy program, ATSN-201, aimed at treating X-linked retinoschisis (XLRS). Additionally, the funds will support Atsena’s preclinic
- Alcon Acquires Majority Interest in Aurion Biotechhttps://modernod.com/news/alcon-acquires-majority-interest-in-aurion-biotech-to-advance-cell-therapy-for-corneal-endothelial-disease/2482718/Alcon announced it has acquired a majority interest in Aurion Biotech, a clinical-stage company developing cell therapies to treat eye diseases. Financial terms of the deal were not disclosed.
- Bausch + Lomb Announces Voluntary Recall of enVista IOLshttps://modernod.com/news/bausch-lomb-announces-voluntary-recall-of-envista-iols/2482717/In response to an increased number of reports of toxic anterior segment syndrome (TASS), Bausch + Lomb announced a voluntary recall of IOLs on its enVista platform, including the enVista Aspire and enVista Envy IOLs, and certain enVista monofocal lenses in the US. B+
- Surrozen Discontinues Liver Program; Shifts Focus to Ophthalmologyhttps://modernod.com/news/surrozen-discontinues-liver-program-shifts-focus-to-ophthalmology/2482716/Surrozen announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs, including development of new treatment options for retinopathies. The company will use a $175-million private placement
- Unity Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in DMEhttps://modernod.com/news/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-dme/2482712/Unity Biotechnology announced topline results from the phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through 24 weeks, and the majori
- Study: Glaucoma Monitoring Lags in Low-Income and Rural Areashttps://modernod.com/news/study-glaucoma-monitoring-lags-in-low-income-and-rural-areas/2482710/A new Northwestern University study suggests that race, income and where patients live play a major role in the level of care glaucoma patients receive. Researchers found that Black, Hispanic and Asian American patients, as well as those from rural and economically distressed communities, are sig
- Prevent Blindness Announces Matt MacDonald as Chair-Elect of Board of Directorshttps://modernod.com/news/prevent-blindness-announces-matt-macdonald-as-chair-elect-of-board-of-directors/2482708/Prevent Blindness, a nonprofit organization dedicated to eye health and safety awareness, named Matt MacDonald as Chair-elect of its Board of Directors. The vote was held last week during the Spring 2025 Board Meeting. He will succeed current Board of Directors Chair Jim McGrann, CEO of Adva
- Study Finds Most Glaucoma Patients Unaware of Preservative-Free Treatment Optionshttps://modernod.com/news/60-of-glaucoma-patients-unaware-of-preservative-free-treatment-options-study-from-preservative-freedom-coalition/2482698/The Preservative Freedom Coalition announced the results of a new nationwide survey delving into the experience of glaucoma patients to identify opportunities for improved communication with their eye care providers. This comes as Monday kicked o
- Luxa Biotechnology Presents Data from First-in-Human Retinal Pigment Epithelium Cell Therapy for Dry AMDhttps://modernod.com/news/luxa-biotechnology-presents-data-from-first-in-human-retinal-pigment-epithelium-cell-therapy-for-dry-amd/2482693/Luxa Biotechnology announced clinical data from its phase 1/2a clinical trial evaluating RPESC-RPE-4W, a proprietary retinal pigment epithelium (RPE) cell therapy for patients with dry age-related macular degeneration (AMD). The data were presented at the 77th Annual Wills Eye Conference in Phila